Histocell Joins the MAI CDMO Platform for a New Collaboration
We are proud to announce that Histocell, a leader in cell therapies and biologics, is joining the MAI CDMO platform. This collaboration represents a key milestone for both organizations, strengthening our commitment to innovation in the development and manufacturing of advanced medicinal products in regenerative medicine.
With their extensive experience in advanced therapy medicinal products (ATMPs), Histocell has become a benchmark in the industry. Their deep expertise and innovative approach will play a crucial role in driving the continuous growth of our platform, enhancing the manufacturing and development of high-quality cell therapies and biologics.
At MAI CDMO, we always strive to push the boundaries of what’s possible in advanced therapeutic development. This new partnership with Histocell will not only strengthen our capabilities but also enable us to offer more comprehensive solutions to our clients and continue contributing to the progress of regenerative medicine.
We would like to express our gratitude to Histocell for their trust in us. We are confident that this collaboration will bring great success and open new opportunities in the industry.
Stay tuned for more updates on this exciting project!